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Alkylresorcinols are amphiphilic metabolites, well-known for their diverse biological activities, produced by both
prokaryotes and eukaryotes. A few classes of alkylresorcinol scaﬀolds have been reported from the
photoautotrophic cyanobacteria, ranging from the relatively simple hierridins to the more intricate
cylindrocyclophanes. Recently, it has emerged that cyanobacteria employ two diﬀerent biosynthetic pathways
to produce unique alkylresorcinol scaﬀolds. However, these convergent pathways intersect by sharing
biosynthetic elements which lead to common structural motifs. To obtain a broader view of the biochemical
diversity of these compounds in cyanobacteria, we comprehensively cover the isolation, structure, biological
activity and biosynthesis of their mono- and dialkylresorcinols. Moreover, we provide an overview of the
diversity and distribution of alkylresorcinol-generating biosynthetic gene clusters in this phylum and highlight
opportunities for discovery of novel alkylresorcinol scaﬀolds. Because some of these molecules have inspired
notable syntheses, diﬀerent approaches used to build these molecules in the laboratory are showcased.1. Introduction
2. Structural variety and biological activity of alkylresorci-
nols in cyanobacteria
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Alkylresorcinols represent a large structural group of amphi-
philic phenolic lipids. These scaﬀolds are widespread in
Nature—alkylresorcinols have been isolated from higher plants,
insects, fungi, algae, slime molds, mosses and bacteria.1–3 They
play structural roles in the membranes of the producing
organisms, and have been associated with many biological
activities including antioxidant, antibacterial, cytotoxic, der-
matotoxic, genotoxic, and signaling properties.1–3 The chem-
istry, structural diversity and associated biological activity of
alkylresorcinols, mostly from the plant world, has been thor-
oughly reviewed by Kozubek and co-workers.1,2
It has recently emerged that alkylresorcinols are generated by
diﬀerent pathways that sometimes intersect to create furtherNat. Prod. Rep.
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View Article Onlinechemical diversity. The type III polyketide synthase (PKS), which
elongate and cyclize diﬀerent fatty-acyl precursors give rise to
monoalkylresorcinols (MARs) in plants and bacteria and have been
studied for the past few decades.4,5 However, the biosynthesis of
dialkylresorcinols (DARs, so far only encountered in bacteria) was
not fully understood until the recent report of two diﬀerent DAR-
generating pathways. In 2013, the Balskus lab showed that the
unusual paracyclophane DARs derive from dimerization of type III
PKS-derived MAR units.6 In 2014, the Bode group revealed that
a new type of ketosynthase generated 2,5-DARs from two diﬀerent
fatty acid primary metabolism-derived precursors.7
Cyanobacterial alkylresorcinols, in particular DARs, are struc-
turally distinct from those of heterotrophic bacteria, in that they
commonly feature halogenation, glycosylation, long alkyl chains
and intra- or inter-molecular cyclization. Our current under-
standing of alkylresorcinol diversity in cyanobacteria is limited, as
many orphan gene clusters that lead to MARs and DARs are found
in their genomes.8 Despite this small number of cyanobacterial
alkylresorcinols, the structural connections among them are
evident and reect their intertwined biosynthetic pathways. ThisTeresa Martins obtained her BSc
and MSc in Biochemistry from
the University of Porto in 2017.
During her MSc studies, under
the supervision of Dr Pedro
Lea˜o, she focused on the natural
products chemistry of cyanobac-
teria. Teresa has recently been
granted with a PhD scholarship
to study the biosynthesis of
unusual cyanobacterial
secondary metabolites, in the
Cyanobacterial Natural Prod-
ucts group at CIIMAR (Univer-
sity of Porto).
Caroline Rouger graduated in
pharmacy from the University of
Angers where she received her
PhD in 2015, studying preny-
lated polyphenols and their anti-
inammatory and immunomod-
ulatory activities under the
guidance of Prof. Pascal
Richomme and Dr Se´verine
Derbre´. Aer one year as
research and teaching assistant
at the University of Limoges, she
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a position of assistant professor at the University of Bordeaux and
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Nat. Prod. Rep.realization has been the main motivation for the present review.
We begin by covering the structural diversity of the cyanobacterial
alkylresorcinols and their biological activities, before detailing the
biosynthetic pathways that generate such structures. We then peer
into the genomes of cyanobacteria and look into the distribution
of alkylresorcinol-related biosynthetic pathways, including those
without any associated natural product. Since these structures
have inspired a number of total syntheses that contrast with their
natural biosynthesis, some of the strategies that have been used to
obtain cyanobacterial alkylresorcinol scaﬀolds in the laboratory
are briey discussed.2. Structural variety and biological
activity of alkylresorcinols in
cyanobacteria
2.1. Monoalkylresorcinols (MARs)
MARs have been reported from a variety of organisms, mainly
from plants, bacteria and fungi, but also from protists andNathaniel Glasser received his
PhD in 2017 from the California
Institute of Technology under
the supervision of Dr Dianne
Newman, where he studied the
biochemistry of extracellular
electron shuttling. In 2018 he
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human cancer cell lines. She is
currently undertaking PhD
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the supervision of Dr Pedro
Lea˜o.
This journal is © The Royal Society of Chemistry 2019
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View Article Onlinebryozoans.1–3 Biological activities associated with these metab-
olites include anticancer, antifungal, anti-inammatory, anti-
microbial, antiparasitical, antioxidant, genotoxic, among
others.1,2 In higher plants, MARs have been obtained, for
example, from rye and wheat bran oils, mango peals as well as
from leaves and seeds used in ancient traditional medicines.1,2
Structural variations in plant MARs are usually related to the
alkyl substituent; for example, DNA-polymerase inhibiting bis-
5-alkylresorcinols isolated from the angiosperm Panopsis
rubescens9 bear two terminal resorcinol rings on each side of the
alkyl chain. Some additional structural features are noteworthy
in non-plant MARs: for example, monochasiols isolated from
the slime mold Dictyostelium monochasioides contain a chlori-
nated phenolic ring, while adeninealkylresorcinol, isolated
from the fungus Lasiodiplodia sp.,10 features a nucleobase
moiety. O-Methylation is also common in MARs.1Nelly Brugerolle de Fraissinette
is a post-graduate member of the
Cyanobacterial Natural Prod-
ucts group at CIIMAR (Univer-
sity of Porto). Nelly recently
obtained a MSc in Applied Blue
Biotechnology in 2018 (Univer-
sity of La Rochelle), and is
currently a project technician.
Her research interests include
natural product discovery for
biotechnological applications to
the environment and cyano-
bacterial cultivation.
Emily Balskus received her BA
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PhD in synthetic organic chem-
istry from Harvard University,
where she worked with Eric
Jacobsen. Her postdoctoral
studies at Harvard Medical
School with Christopher T.
Walsh focused on deciphering
the biosynthesis of cyanobacte-
rial sunscreens. She began her
independent career at Harvard
University in 2011 and is now
a Professor of Chemistry and Chemical Biology. Her research
program explores the intersection of organic chemistry, biochem-
istry, and microbiology, with a major focus on understanding
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This journal is © The Royal Society of Chemistry 2019In heterotrophic bacteria, MARs have been reported from
Actinobacteria and alpha-, delta- and gamma-Proteobacteria11–13
which also include sulfated, methylated, and glycosylated
resorcinol variants (Fig. 1). Interestingly, AzotobacterMARs were
found to be the main components of its cyst membranes14,15 and
are essential for the encystment process.16 In Streptomyces sp.,
MARs were found to be associated with the cytoplasmic
membrane and to confer b-lactam antibiotic resistance.17
Despite the large number of type III PKS-containing
biosynthetic gene clusters (BGCs) found in cyanobacterial
genomes (see Section 3), only four cyanobacterial MARs (hier-
ridins A–C18,19 and cylindrofridin A,20 4–7) are known to date.
2.1.1. Hierridins. Hierridins are a group of mono-
alkylresorcinols isolated in 1992 by Gonza´lez et al.23 for the rst
time from a lichen, Ramalina hierrensis, that is endemic to the
Canary Islands. Hierridin (8) was isolated as a solid compound
and the arrangement of the substituents was claried via semi-Deniz Tasdemir obtained her
PhD degree in phytochemistry in
1997 at ETH-Zurich. She then
carried out post-doctoral
research with Prof. Chris M.
Ireland at University of Utah on
anticancer marine sponge
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marine biodiscovery at National
University of Ireland Galway
(2011–2014). Currently she is full professor of marine natural
product chemistry at GEOMAR Helmholtz Centre for Ocean
Research Kiel. Her research interests include marine biotech-
nology, drug discovery, metabolomics and chemical ecology of
marine invertebrates, seaweeds, seagrasses and microorganisms.
Pedro Lea˜o obtained his PhD
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athy in cyanobacteria under the
supervision of Prof. Vitor Vas-
concelos. For his postdoctoral
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Gerwick lab (Scripps Institution
of Oceanography) and Balskus
group (Harvard University). In
2015 he became Auxiliary Researcher at CIIMAR and in 2018 he
started the Cyanobacterial Natural Products group in the same
institution. His research interests lie in the chemistry, biosynthesis
and chemical ecology of cyanobacterial secondary metabolites.
Nat. Prod. Rep.
Fig. 1 Examples of MARs isolated from diﬀerent heterotrophic
bacteria, namely a glycolipid from the cysts of Azotobacter vinelandii
(1),15 the main component of the beta-leprosol mixture from Myco-
bacterium leprae (2)21 and one of the components of panosialin from
Streptomyces spp. (3).22 Compound 1 shows the numbering scheme
used throughout the text to refer to resorcinol ring substituents.
Natural Product Reports Review
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View Article Onlinesynthesis of its acetylated version (9). Until then, only a primin
derivative24 had been reported from the plant Primula obconica
with a similar structure to 8. In 1998, Papendorf et al.18 isolated
the rst cyanobacterial MARs from the lamentous Phormidium
ectocarpi (SAG 60.90), guided by the antimalarial activity of its
dichloromethane extract against Plasmodium falciparum.
During the isolation process, the team realized that the active
extract had two components, which could be discriminated by
gas chromatography-mass spectrometry analysis as hierridins A
(4) and B (5). The former had been reported in the same year
from the yeast Phaﬃa rhodozyma, under the trivial name phaf-
aol.25 The mixture of the two hierridins demonstrated anti-
plasmodial activity when tested against clones D6 (chloroquine
sensitive) and W2 (chloroquine resistant) with IC50 values of 5.2
mg mL1 and 3.7 mg mL1, respectively18 (see Table 1 for
a summary of the biological activities associated with cyano-
bacterial alkylresorcinols).
Hierridin B was later reported from a marine picocyano-
bacterium (Cyanobium sp. LEGE 06113), collected from the
Portuguese coast.26 To further interrogate its biological prop-
erties, metabolite 5 was tested against eight human cell linesNat. Prod. Rep.showing selective albeit very mild cytotoxicity to a colon
adenocarcinoma cell line HT-29, with an IC50 value of100 mM.
This selective bioactivity was further investigated by Freitas
et al.27 Compound 5 seems to interfere with VDAC-1 (voltage-
dependent anion-selective channel 1) in mitochondria as well
as some cell cycle and structural genes responsible for the cell
cycle checkpoints, leading to apoptosis in the HT-29 cells.
During the re-isolation of 5, a halogenated analogue, hier-
ridin C (6) was discovered.19 The aromatic ring of this metabo-
lite has a chlorine atom adjacent to the alkyl-substituted
carbon, conrmed through NMR and MS experiments.
Compound 6 showed antimalarial activity against Plasmodium
falciparum strains (3D7 and Dd2) with IC50 values of 1.5 mM and
2.3 mM, respectively. This is the rst bacterial example of a MAR
featuring ring halogenation. Curiously, the structurally-related
monochasiols possessing a chlorination in position 2 of the
resorcinol ring were recently reported from a Dictyostelium
slime mold28 and are related to Dictyostelium diﬀerentiation-
inducing (DIF) polyketides.29 Similar to hierridin B, the DIF-
family compound DIF-3 targets mitochondria in cancer cells.30
2.1.2. Cylindrofridin A. The metabolite cylindrofridin A (7)
was discovered by Preisitsch et al.20 and corresponds to
a monomeric unit that likely acts as an intermediate in the
biosynthesis of the cylindrocyclophanes (see Sections 2.2.1. and
3.2.1.). Compound 7 features halogenation and methylation in
the u-5 and u-10 positions of its alkyl chain, respectively, and is
also acetylated in its benzylic position. The compound was
isolated in a screening study of dozens of cyanobacterial strains,
by means of an extraction and detection strategy aimed at
identifying paracyclophane-related molecules. Metabolite 7
showed mild antibacterial activity towards Gram-positive
bacteria, including MRSA.20 Interestingly, while investigating
the biosynthesis of the cylindrocyclophanes, Nakamura et al.6
observed potent toxicity eﬀects of a synthetic analogue of 7
towards a cylindrocyclophane-producing strain of Cylin-
drospermum licheniforme.2.2. Dialkylresorcinols
DARs have been known for a few decades, with exirubin (10)31
and 2-n-hexyl-5-n-propylresorcinol (also referred as DB-2073,
11)32 being the rst described compounds of this family.
While exirubin-type pigments have so far only been reported
from Flexibacter, Flavobacteria and Cytophaga strains,33 the
description of the potent antibiotic DB-2073 marked the
discovery of a series of DARs from Pseudomonas spp. Examples
include resorstatin (2-hexyl-5-pentylresorcinol, 12), showing
a strong inhibitory activity against lipid peroxidation induced
by free radicals in rat brain homogenate (IC50 ¼ 2.06 mM)34 and
other short-chain DARs such as 2-butyl-5-propylresorcinol (13)
and 2-hexyl-5-methylresorcinol (14) that show antibacterial or
antifungal activity.35 More recently, arcuavin (15), a xantho-
monadin-DAR hybrid that bears resemblance to the exirubin
pigments was reported from an Azoarcus sp. b-proteobacte-
rium.36 The structures, biosynthesis and biological role of
bacterial DARs (mostly from heterotrophic bacteria) have been
reviewed by Scho¨ner et al.37This journal is © The Royal Society of Chemistry 2019
Table 1 Biological activity of cyanobacterial alkylresorcinols
Alkylresorcinol class Congener(s) Reported biological activity
Potencya
(in mM, unless
otherwise stated)
MARs
Hierridins A (4) and B (5), mixture Antiplasmodial
(Plasmodium falciparum, D6 and W2 strains)18
3.7–5.2 mg mL1 (IC50)
B (5) Cytotoxic (HT-29 cells)26 100 (IC50)
B (5) and C (6) Antiplasmodial (P. falciparum, 3D7 and Dd2 strains)19 1.5–2.3 (IC50)
Cylindrofridins A (7) Antibacterial (Gram-positive:
MRSA, Streptococcus pneumoniae)20
8.6–17 (MIC)
Cytotoxic (HaCaT cells)20 100 (IC50)
DARs
Bartolosides A (58) Cytotoxic (HT-29 cells)51 21 (IC50)
A (58), E (62) and I (66) Cytotoxic (T-47D, MG-63, RKO cells)52 22–60 (IC50)
B (59) Cytotoxic (T-47D, MG-63, HepG2,
SH-SY5Y, PC-3, HT-29, RKO cells)51
9.5–26 (IC50)
Carbamidocyclophanes A–C (35–37) Antibacterial (Staphylococcus aureus)44 40–100 (MIC)
Cytotoxic (FI and MCF7 cells)44 0.86–5.1 (IC50)
Antibacterialb (S. pneumoniae)45 5.6–8.2 (MIC)
A–C (35–37), F (40) and G (41) Antibacterial (Enterococcus faecalis, S. aureus)45 0.1–1.1 (MIC)
A (35), B (36) and F (40) Antifungal (Candida albicans)45 1.3–5.5 (MIC)
F (40) and G (41) Antimycobacterial (Mycobacterium tuberculosis)45 0.8–1.8 (MIC)c,
5.4 (MIC)d,e
A–F (35–40) and H–L (42–46) Antibacterial (Gram positive: MRSA and S. pneumoniae)46 0.10–0.32(MIC)
Cytotoxic (HaCaT cells)46 2.8–7.6 (IC50)
A (35) and F (40) Cytotoxic (MDA-MB-435, MDA-MB-231 and OVCAR3 cells)48 1.0–4.3 (IC50)
Cylindrocyclophanes A (16) and A4–A1 (26–29) Antibacterial (Gram positive: MRSA and S. pneumoniae)
46 0.43–2.10 (MIC)
Cytotoxicity (HaCaT cells)46 5.0–11.5 (IC50)
A–F (16, 21–25) Cytotoxic (KB cells)39 0.5–5 mg mL1 (IC50)
A (16), C (22), A4–A1 (26–29),
C4 (30), C2 (32) and F4 (34)
20S proteasome inhibition42 2.55–59.3 (IC50)
A4–A2 (26–28), C4 (30) and C2 (32) Cytotoxic (HT-29 cells)
42 0.5–2.8 (EC50)
D (23) Cytotoxic (MDA-MB-435 and MDA-MB-231 cells)49 2.3–5.2 (IC50)
F (25) Cytotoxic (MDA-MB-435, MDA-MB-231 and OVCAR3 cells)48 10–13 (IC50)
Merocyclophanes A (47) and B (48) Cytotoxic (HT-29 cells)47 1.7–3.3 (IC50)
A (47), C (49) and D (50) Cytotoxic (MDA-MB-435, MDA-MB-231 and OVCAR3 cells)48 0.9–9.8 (IC50)
Nostocyclophanes A–D (18–20, 17) Cytotoxic (KB and LoVo cells)43 0.5–2 mg mL1 (IC50)
Nostocyclyne A (70) Antibacterial (S. aureus and Bacillus subtilis)54 10–12.5 mg/disk (MIC)
Ribocyclophanes A–D (51–54) Cytotoxic (MDA-MB-435 and MDA-MB-231 cells)49 0.6–6.4 (IC50)
a As reported in the cited references. b Compounds 35 and 36 only. c FromMABA (microplate alamar blue assay). d From LORA (low-oxygen recovery
assay). e MIC value corresponds to compound 40, compound 41 was reported to have a MIC > 10 mM.
This journal is © The Royal Society of Chemistry 2019
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View Article OnlineThe rst cyanobacterial DARs were discovered in the early
1990s when Richard Moore's lab described the highly unusual
structures of a new class of naturally-occurring cyclic DARs:
a series of cyclophanes isolated from Nostocales strains.38,39
Since then, a number of DARs have been reported from cya-
nobacteria, most of which diﬀer structurally from their non-
cyanobacterial counterparts and have a variety of biological
activities. Many structural features are shared by diﬀerent
classes of cyanobacterial DARs, including chlorination, alkyne
moieties and glycosylations, which reects common biosyn-
thetic elements (see Section 3.2) but also suggests that these
compounds share biological roles.
2.2.1. [n.n]Cyclophanes and cylindrofridins. The cyclo-
phane nomenclature was suggested by Cram & Steinberg40
following their eﬀort to synthesize molecules with unique
complementary three-dimensional structures, considered asNat. Prod. Rep.
Natural Product Reports Review
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View Article Onlineinteresting vehicles for host–guest chemistry. Many and diverse
structural motifs that are found within the natural product
space fall into the cyclophane category sensu lato.41 The cyclo-
phanes found in cyanobacteria belong to the [7.7]para-
cyclophanes, in which two p-substituted aromatic units are
bridged by seven carbon atoms. More precisely, these cyano-
bacterial metabolites share a unique scaﬀold consisting of two
resorcinol moieties connected via two aliphatic chains and are
divided into diﬀerent structural subclasses, namely the cylin-
drocyclophanes,38,39,42 nostocyclophanes,38,43 carbamidocyclo-
phanes,44–46merocyclophanes47,48 and ribocyclophanes49 (Fig. 2).
The cylindrocyclophanes and nostocyclophanes were discov-
ered on the basis of antitumor activity showed by two Nosto-
cales cyanobacterial extracts.38 The bioassay-guided isolation
led to the structure elucidations of cylindrocyclophane A (16)
and halogenated nostocyclophane D (17), from Cylin-
drospermum licheniforme ATTC 29204 and Nostoc linckia UTEX
B1932, respectively. The absolute stereochemistry of the halo-
genated metabolite 17 was determined using X-ray crystallog-
raphy.38 In the following years, the same team describedFig. 2 Cyanobacterial [7.7]paracyclophanes (16–47, 49–54) and related
Nat. Prod. Rep.nostocyclophanes A–C (18–20),43 and cylindrocyclophanes B–F
(21–25),39 which were also discovered based on their cytotoxicity
towards human cancer cell lines. The mid-chain chlorinations
are the hallmark of the nostocyclophanes, while all the cylin-
drocyclophanes feature a methyl substituent adjacent to the
benzylic positions. The cylindrocyclophane class was later
expanded following the 20S proteasome inhibition activity-
guided discovery of congeners A4–A1 (26–29), C4–C1 (30–33)
and F4 (34) fromNostoc sp. UIC 10022A that feature chlorination
in the terminal alkyl chain positions.42
The carbamidocyclophanes are characterized by carbamate
substituents at both benzylic positions. Carbamidocyclophanes
A–E (35–39) were isolated from a Vietnamese Nostoc sp. strain,
guided by antibacterial activity towards Gram-positive bacteria
as well as antifungal (Candida maltosa) activity.44 These
metabolites showedmild potency towards Staphylococcus aureus
ATCC 6538 but had stronger, low micromolar cytotoxicity
towards MCF7 breast adenocarcinoma cells indicating that
cyanobacterial paracyclophanes exhibit generalized cytotox-
icity.44 The congeners F (40) and G (41) are similar to 35 butmetabolites (48, 55–57).
This journal is © The Royal Society of Chemistry 2019
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View Article Onlinefeature hydroxyl and acetyl substituents, respectively, in one of
the benzylic positions. Both metabolites showed sub-
micromolar cytotoxicity towards human cancer cell lines.45
Notably, compound 40 exhibited potent anti-Mycobacterium
activity and was also reported to strongly inhibit the growth ofS. aureus and Enterococcus faecalis.45 Five new carbamidocyclo-
phanes (42–46) with minor structural diﬀerences to known
congeners were later reported by the same research group,46 and
exhibited submicromolar antibacterial (Gram-positive) activity
and low-micromolar cytotoxicity in a human keratinocyte
cellular assay.
Merocyclophanes have a benzylic methyl substituent and lack
the beta methyl group found in the cylindrocyclophanes. Mer-
ocyclophane A (47) was isolated from a terrestrial Nostoc sp.
strain (UIC 10062) together with the hydroxyquinone-containing
analogue merocyclophane B (48).47 Merocyclophanes C (49) and
D (50) were later isolated from the freshwater Nostoc sp. UIC
10110 and are analogues of 47 with hydroxylation at one or both
terminal alkyl positions.48 The merocyclophanes, as with most
cyanobacterial paracyclophanes, are strongly cytotoxic (low-to-
sub micromolar IC50) towards human cancer cell lines.47,48
Recently, the Orjala group reported members of a new class
of paracyclophanes, namely ribocyclophanes A–D (51–54), that
contain b-D-ribopyranose as substituent at one or both benzylic
positions.49 These sugar moieties were found to be in the rare
1C4 conformation; the authors suggest that this is due to steric
hindrance from the cylindrocyclophane core not allowing the
more common (and typically more stable) 4C1 conformation.
The ribocyclophanes were co-isolated with cylindrocyclophane
D (23) suggesting a common biosynthetic origin.49
The isolation of pharacine, a highly symmetrical para-
cyclophane (a cyclic terephthalate), from the gliding marine
Gram-negative bacterial strain Cytophaga sp. (AM13.1),This journal is © The Royal Society of Chemistry 2019suggested that the occurrence of [n.n]cyclophanes is not
restricted to the phylum Cyanobacteria.50 Still, the presence of
traces of this molecule in ubiquitous phthalate plasticizers has
raised doubts as to the natural origin of the compound.50In 2015, Preisitsch and collaborators20 isolated two new
cylindrocyclophane-related DARs, cylindrofridins B (55) and C
(56). These compounds are dimers of the co-isolated MAR 7 or
its putative deacetylatedmonomer (that has not been isolated to
date) and are reminiscent of the Friedel–Cras alkylation events
that are involved in cyanobacterial paracyclophane biosyn-
thesis8 (see Section 3.2.1.). This is evident from the chlorination
at the u-5 carbon atom in cylindrofridins, the site of [7.7]para-
cyclophane macrocycle formation, and therefore compounds 55
and 56 represent linearized biosynthetic intermediates of the
cylindrocyclophanes.20 Likewise, the recently described ribocy-
clophane E (57), isolated from the ribocyclophane-producing
strain Nostoc sp. UIC 10366,49 is a linearized version of
compound 54. No signicant bioactivity has been reported for
compounds 55–57, indicating that the open versions of the
cyclophane macrocycles do not conserve their cytotoxic and
antibacterial properties.20,49
2.2.2. Bartolosides. While screening cultured cyanobac-
teria obtained from the Portuguese coast for novel natural
products, Lea˜o et al.51 discovered an unprecedented group of
DAR glycolipids, named bartolosides A–D (58–61). These
compounds were isolated from the phylogenetically distant
cyanobacterial genera Nodosilinea and Synechocystis. Examina-
tion of a fractionated crude organic extract of the lamentous
cyanobacterium Nodosilinea nodulosa LEGE 06102 led to the 1H
NMR spectroscopy-guided isolation of compound 58. Subse-
quently, an independent bioassay-guided fractionation of the
crude extract of Synechocystis salina LEGE 06155, a unicellular,Nat. Prod. Rep.
Natural Product Reports Review
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View Article Onlinefree-living cyanobacterium found at the same beach as the
producer of bartoloside A (58), led to the isolation of analogous
metabolites, namely bartolosides B, C and D (59, 60 and 61).
The authors hypothesized that, taking into account the phylo-
genetic distance between the two producing strains, coupled
with their geographical co-occurrence, horizontal gene transfer
of the bartoloside metabolic pathway may have occurred.51 The
bartolosides share a core DARmotif, with long alkyl chains with
at least one being chlorinated. In addition, the resorcinol ring
itself is decorated with an O-linked xylose residue in 58 and C-
linked xylose as well as O-linked rhamnose in 59–61. The very
similar halogenated alkyl substituents in the DAR scaﬀold
complicated structural elucidation using standard spectroscopy
and spectrometric techniques. As the compounds were recal-
citrant to crystallization, only by inferring the positioning of
each of the two alkyl chains in 59 from biosynthetic studies was
it possible to fully elucidate its planar structure by interpreta-
tion of NMR and MSn data. The planar structures of 58, 60 and
61, were then elucidated by comparison of their spectroscopic
data with that of 59.51
In a later study using the cyanobacterium S. salina LEGE
06099, closely related to the bartolosides B–D (59–61) producer
(S. salina LEGE 06155), Afonso et al.52 reported new analogues of
metabolite 58, bartolosides E–K (62–68) by following cytotoxic
activity towards cancer cell lines. Most of the structural diﬀer-
ences of these new analogues related to the length of the alkyl
chain and the presence or absence of a chlorine substituent in the
5-alkyl chain. A notable exception is compound 66 that features
a rare, mid-chain gem-dichloro moiety.52 Interestingly, this same
strain produced bartoloside A in elevated amounts (reaching up to
0.6% of its dry weight), suggesting a potential structural role.52
The bartolosides have been tested for cytotoxicity towards several
cancer cell lines but showed only mild activity with compound 59
being the most potent of the series (IC50 value 9 mM against PC-3
human prostate adenocarcinoma).51,52
2.2.3. Microcarbonin A. In 2006, Beresovsky and collabo-
rators53 reported microcarbonin A (69), a metabolite produced
by a Microcystis sp. strain (MB-K) collected from the Israelian
freshwater Lake Kinneret. During bioassay-guided isolation,
fractions containing 69 demonstrated a highly specic activity
in inhibiting photosynthesis and causing the death of the
dinoagellate Peridinium gatunense by abolishing its internal
carbonic anhydrase activity. However, a gradual loss of its
allelopathic activity toward the nal step of the purication
process was observed. This was attributed to the synergistic
eﬀect of the fatty acids residing with microcarbonin A in the
partially puried fractions.53 Compound 69 features a rare 1-
aryl-1,3-diyne in its 5-alkyl substituent and a fully aliphatic 2-
alkyl chain. Among the cyanobacterial DARs, it is metabolite 69
that most closely resembles DARs from heterotrophic bacteria.
2.2.4. Nostocyclyne A. Following a bacterial sampling
campaign aiming at understanding the massive death of the
fern Adiantum capillus veneris in a greenhouse of Newe Mono-
sson (Israel), Ploutno & Carmeli54 rst described nostocyclyne A
(70). The compound was the major active metabolite produced
during a bloom of the terrestrial cyanobacterium Nostoc sp.
(TAU strain IL-220) that was thought to be associated with theNat. Prod. Rep.observed plant mortality.54 Pure 70 did not show promising
bioactivity towards Gram-negative bacteria, and it had only mild
activity towards Gram-positives.54 Apart from the rare ene-
diynes,55 compound 70 is, to the best of our knowledge, the only
other example of a cyclic alkyne natural product. Curiously, 70
combines features of the cyclophanes (mid-alkyl chain C–C
bond with resorcinol ring) with an internal alkyne moiety,
which is in turn found in compound 69.3. Biosynthesis of alkylresorcinols in
cyanobacteria
3.1. Monoalkylresorcinols from type III PKS pathways
MARs are, to date, known only to be biosynthesized via type III
PKS enzymes. Homodimeric and iterative, type III PKSs are
typically smaller and simpler than type I and II PKS, but they
retain nonetheless elongation and cyclization functionalities.4
Generally, type III PKSs use a thioester as the starter unit and
perform elongation through the condensation of extender
units, usually malonyl-CoA, to form a polyketide chain that is
then intramolecularly cyclized via aldol condensation, Claisen
condensation or lactonization.56 Despite the simplicity of their
reactivity, by diversifying the starter and extender units, number
of condensation steps and cyclization mechanisms, these
enzymes are responsible for the biosynthesis of a breadth of
compounds, not only alkylresorcinols but also alkylpyrones,
chalcones, stilbenes, quinolones and acylphloroglucinols,
among other.57,58 MARs are generated by a specialized group of
type III PKS, the alkylresorcinol synthases (ARS), which catalyze
the condensation between fatty acyl-CoA (or- ACP) thioesters
(starter units) and malonyl-CoA thioesters (or other extender
units), followed by an aldol-type cyclization. Most of the
currently characterized ARSs are bacterial, and only few plant
and fungi-derived examples are known.5 The rst ARS enzyme,
ArsB, which was characterized in 2006 from Azotobacter vine-
landii, is involved in the biosynthesis of cyst envelope alkylre-
sorcinols (e.g. compound 1).16 Since then, a few other homologs
have been characterized, namely SrsA from Streptomyces gri-
seus17 (that produces 6-methyl-5-alkylresorcinols), MMAR_2470
and MMAR_2474 from Mycobacterium marinum which provide
methylated alkylresorcinols,59 the alkylresorcylic acid-
generating FtpA from Myxococcus xanthus,13 BpsA from
Bacillus subtilis which produces long-chain MARs,60 as well as
DpgA61 and DhpaS57 which produce the MAR (S)-3,5-dihydrox-
yphenylglycine (a common moiety in actinobacterial glycopep-
tide antibiotics).
Apart from theMAR-mediated biosynthesis of cyanobacterial
cyclophanes6 (see Section 3.2.1.), only very recently the rst
cyanobacterial biosynthetic pathway leading to MAR end
products (hierridins 5 and 6) has been reported.19 The hid BGC
was found in the genome of the hierridin-producer Cyanobium
sp. LEGE 06113 by mining it for type III PKSs. This small BGC
codes for three proteins with functions consistent with hier-
ridin biosynthesis: a type-III PKS (HidC), a SAM-dependent
methyltransferase (HidA) and a FAD-dependent oxidoreduc-
tase (HidB) (Fig. 3). Based on in vivo assays and the biosyntheticThis journal is © The Royal Society of Chemistry 2019
Fig. 3 Biosynthesis of hierridins. Top – Hierridin biosynthetic gene cluster (hid). Bottom – Proposed19 biosynthesis of hierridins B (5) and C (6).
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View Article Onlinelogic associated with Hid enzymes, hierridin biosynthesis puta-
tively involves four main steps. First, HidC accepts thioester-
activated palmitic acid and performs four elongation steps with
malonyl-CoA and nally a decarboxylative condensation (C2-to-
C7 aldol condensation) forms the alkylresorcinol ring (Fig. 3).
Methylation of resorcinol phenol groups by HidA likely ensues,
since a recombinant version of HidA was able to methylate
5-pentadecylresorcinol.19 This observation not only established
experimentally the involvement of the hid BGC in hierridin
biosynthesis, but also suggested that methylation precedes HidB-
mediated hydroxylation of the resorcinol ring to yield hierridin B
(5). The last biosynthetic step involves regioselective chlorination
of 5 generating hierridin C (6). However, as observed for the
resorcinol-halogenated bartolosides, the hid BGC does not
encode a halogenase and no halogenase was found in the
genome of Cyanobium sp. LEGE 06113, and so the nature of this
halogenation is still unknown. Lea˜o et al.19 report that hid-like
BGCs are present in many cyanobacterial genomes, most preva-
lently in those of picocyanobacteria (see also Section 3.3).
3.2. Dialkylresorcinols
3.2.1. Frommonoalkylresorcinol dimerization. The natural
paracyclophanes contain an unusual dialkylresorcinol motif
and symmetrical structures with an intriguing biosynthetic
origin.62 Nevertheless, the complete biosynthetic pathway for
natural paracyclophanes eluded discovery for many yearsFig. 4 Key ﬁndings that provided insight into the overall biosynthesis of c
produce cylindrocyclophanes with a distinctive labeling pattern. [1,2-13C]a
with the 1- and 2-positions of acetate incorporated into speciﬁc position
the site of carbon–carbon bond formation, matched a retrosynthetic hyp
monomeric precursor to cylindrocyclophane D (23), while cylindro
macrocyclization.
This journal is © The Royal Society of Chemistry 2019because it involves a cryptic activation step. The nal dia-
lkylresorcinol is formed from a head-to-tail dimerization of two
monoalkylresorcinol precursors. Paracyclophane biosynthesis
has been studied by a combination of isotope labeling experi-
ments, bioinformatics and biochemistry, and the key biosyn-
thetic steps are now generally understood, with the essential
enzyme activities having been demonstrated in vitro.
The rst insights into paracyclophane biosynthesis came
from feeding studies with isotopically labeled acetate. Bobzin
and Moore fed a mixture of unlabeled and [1,2-13C2]-labeled
acetate to the cylindrocyclophane producer Cylindrospermum
licheniforme ATCC 29204.62 The resulting cylindrocyclophane D
contained adjacent 13C atoms in specic positions (Fig. 4),
indicating that acetate is incorporated into the nal product.
Feeding of [1-13C,2H3]acetate and [2-
13C,2H3]acetate further
indicated that the C-1 and C-2 positions of acetate are incor-
porated as expected for an aromatic polyketide (Fig. 4). Similar
results were also obtained from the nostocyclophane producer
Nostoc linckia UTEX B1932.62 From these data, and the 2-fold
symmetry of the paracyclophane scaﬀold, Bobzin and Moore
correctly proposed that natural paracyclophanes are bio-
synthesized from a polyketide-derived alkylresorcinol precursor
that undergoes dimerization and that the b-methyl groups in
compound 23 were derived from acetate and not from methio-
nine.62 This realization was key to the Balskus' group strategy
for the discovery of the biosynthetic gene cluster forylindrocyclophanes. (A) Feeding experiments with 13C-labeled acetate
cetate produces adjacent 13C atoms in the positions indicated in green,
s. (B) Discovery of the cylindrofridins, which contain a chlorine atom at
othesis for the origin of cylindrocyclophanes. Cylindrofridin A (7) is the
fridins B (55) and C (56) likely represent the product of partial
Nat. Prod. Rep.
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View Article Onlinecylindrocyclophanes (cyl).6,63 Because b-methyl groups are
introduced into polyketides by a highly-conserved pathway that
includes a homolog of hydroxymethylglutaryl-CoA (HMG-CoA)
synthase, using degenerate PCR and whole-genome
sequencing, Nakamura et al.6 identied an HMG-CoA syn-
thase homolog in the cylindrocyclophane producer C. lichen-
iforme ATCC 29412. The HMG-CoA synthase homolog gene
(cylF) was found to be part of a gene cluster (cylA-P) that encodes
other enzymes whose predicted activities appeared related to
cylindrocyclophane biosynthesis.6 The cluster's biosynthetic
role was conrmed by heterologous expression and purication
of the type III PKS CylI, which was shown to convert a diketide
into an alkylresorcinol that resembles the putative precursor of
cylindrocyclophane biosynthesis.6
The cyl cluster contains an abbreviated set of polyketide
synthases that perform only four elongation reactions. This
activity is insuﬃcient to explain the biosynthesis of the para-
cyclophane alkyl chain. Feeding studies with d19-decanoic acid
led to the production of d18- and d36-cylindrocyclophane F,6
indicating that the alkyl tail originates from fatty acids instead
of from a polyketide, which is nonetheless consistent with the
original feeding studies of Bobzin andMoore.62 Purication and
characterization of CylA and CylB, a fatty acid adenylating
enzyme and acyl carrier protein (ACP), respectively, further
conrmed that cylindrocyclophane biosynthesis begins with the
recruitment of free decanoic acid.6 Because the alkyl chain of
decanoic acid is incorporated into cylindrocyclophanes in toto,
the dimerizing macrocyclization event necessarily requires
functionalization of an unactivated carbon center.6 However,
the true identity of the activated precursor remained elusive
because it was not initially detected in culture extracts.6,63
The dimerization mechanism was claried with the
discovery of the cylindrofridins from other cylindrocyclophane
producers.20 Cylindrofridins 55 and 56 are nearly chemically
identical to the cylindrocyclophanes, except that one of the
dialkylresorcinol motifs is disconnected. Instead, a chlorine
atom occupies the position of C–C bond formation in one alkyl
tail (Fig. 4). Chlorination had been proposed as an activating
step that might allow dimerization using a Friedel–Cras-style
alkylation,63 suggesting the cylindrofridins represent an
incomplete macrocyclization or intermediate of cylin-
drocyclophane biosynthesis. The corresponding halogenase,
CylC, was identied based on a bioinformatic analysis which
revealed that CylC homologs are present in the biosynthetic
gene clusters for certain halogenated products from cyanobac-
teria.8 Using heterologous protein expression and purication,
Nakamura et al.8 demonstrated that CylC chlorinates ACP-
bound decanoic acid early in cylindrocyclophane biosynthesis.
The macrocyclizing enzyme was initially thought to be
CylP,63,64 a predicted Rieske oxygenase that shares homology to
a C–C bond-forming enzyme in streptorubin B biosynthesis,65
but in vitro assays demonstrated that CylP instead installs the a-
hydroxy group of cylindrocyclophanes.8 Further enzyme puri-
cation and in vitro assays showed that CylK, initially annotated
as a hemolysin-type calcium-binding protein, is in fact the
macrocyclizing C–C bond-forming enzyme that completes
cylindrocyclophane biosynthesis.8 CylK uses the chlorinatedNat. Prod. Rep.alkyl tail to perform a Friedel–Cras-style alkylation reaction
with the monoalkylresorcinol to form the nal DAR, a reaction
that removes the chlorine group from the nal product.
Together, a combination of bioinformatics and in vitro
enzymology6,8 provides a comprehensive picture of cylin-
drocyclophane biosynthesis (outlined in Fig. 5). Biosynthesis
starts with free decanoic acid, presumably recruited from fatty
acid biosynthesis or degradation. The fatty-acyl AMP ligase CylA
loads free decanoic acid onto the ACP CylB. The halogenase
CylC then chlorinates the ACP-loaded decanoic acid, and the
chlorination is maintained until the nal macrocyclization
event. Following an initial extension by the PKS CylD (module
1), the HMG-CoA synthase homolog CylF installs the function-
ality that eventually becomes the b-methyl group, likely working
with CylE to incorporate malonyl-CoA, leading to an acetate-
derived b-methyl group. A substituted olen is briey intro-
duced by the enoyl-CoA hydratase CylG. The PKS CylH (module
2) performs decarboxylation and olen reduction to complete
the b-methyl group and then further extends the precursor by
one ketide subunit. The assembly line is terminated by the type
III PKS CylI, which performs two more elongations and releases
the product through ketide cyclization, forming a completed
monoalkylresorcinol precursor. The precursor can be further
decorated by the hydroxylase CylP to install an a-hydroxy group
and then acetylated, likely by the predicted acetylase CylO, to
create the diversity of cylindrocyclophanes observed from live
cultures. Decoration at this stage, rather than following mac-
rocyclization, is supported by the isolation of cylindrofridin A
(7) which is predecorated with an a-acetyl group.20 Finally, the
calcium-dependent enzyme CylK forms the nal cylin-
drocyclophane product by dimerizing two precursors in a Frie-
del–Cras-style alkylation reaction.
Biosynthesis of the other natural paracyclophanes, including
nostocyclophanes, carbamidocyclophanes, and mer-
ocyclophanes, likely follows a similar scheme, and producers of
the latter two are known to contain homologs of the key
biosynthetic enzymes including CylC, CylK, and CylI48,64 (Fig. 5).
The primary diﬀerence in biosynthesis is the enzymes that
decorate the monoalkylresorcinol precursor. The biosynthetic
gene cluster for carbamidocyclophanes contains a predicted
carbamoyltransferase that likely installs the amide group.64 The
biosynthetic gene cluster for merocyclophanes lacks homologs
of CylE–G, the enzymes responsible for b-methyl incorporation,
and the CylH homolog lacks the ECH and ER domains involved
in completing the b-methyl group. Instead, the CylD homolog
contains a predicted methyltransferase domain that likely
incorporates the a-methyl group of the merocyclophanes.48 The
only known producer of nostocyclophanes,38 Nostoc linckia
UTEX B1932, is no longer available from the UTEX culture
collection, and consequently a genetic analysis has yet to be
performed. However, it is anticipated that nostocyclophane
biosynthesis is essentially equivalent to cylindrocyclophane
biosynthesis, with the internal chlorine atom being introduced
by a decorating halogenase prior to macrocyclization and a gly-
cosyltransferase adding the glucose moiety to the resorcinol
ring (for compounds 18 and 19). The other uncharacterized
enzymes in the cylindrocyclophane biosynthetic gene clusterThis journal is © The Royal Society of Chemistry 2019
Fig. 5 Biosynthesis of cyanobacterial cyclophanes. Overview of the BGCs for diﬀerent cyclophane classes (top) and biosynthetic pathway for the
cylindrocyclophanes (bottom), as illustrated by cylindrocylophane D (23). Enzymes that have been puriﬁed and characterized in vitro6,8 are shown
in bold.
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View Article Online(CylJ, CylL, CylM, and CylN) may provide other as-yet undis-
covered decorations to the paracyclophane scaﬀold. For
example, the ribocyclophanes (51–54, 57)49 might originate
from the action of CylN, annotated as a glycosyltransferase.8
3.2.2. From monoalkylresorcinol intramolecular cycliza-
tion. Echoing the original proposal for paracyclophane
biosynthesis, Ploutno and Carmeli hypothesized that the
entirety of nostocyclyne A (70) originates from a polyketide
precursor54 (Fig. 6). However, in light of the known steps for
cylindrocyclophane biosynthesis, the structure of 70 suggests it
might have a similar biosynthetic origin to the cyanobacterialThis journal is © The Royal Society of Chemistry 2019paracyclophanes, where a fatty acid precursor is functionalized
and intramolecularly cyclized using homologs of CylC and CylK,
with the monoalkylresorcinol being synthesized by a homolog
of CylI (Fig. 6). The presence of a single internal alkyne bond is
especially interesting, as the enzymes that give rise to internal
alkynes are poorly documented. Unfortunately, Ploutno and
Carmeli noted that the Nostoc strain isolated from the bloom
material (from which 70 was isolated) did not produce the
metabolite under laboratory conditions,54 suggesting the strain
is either not the native producer or that 70 is the degradation
product of a parent molecule. An investigation of cyanobacteriaNat. Prod. Rep.
Fig. 6 Biosynthetic hypotheses for the origin of nostocyclyne A. (A) The original hypothesis by Ploutno and Carmeli.54 Dashed lines indicate
eventual ring-closing events. (B) An alternative hypothesis based on the elucidation of cylindrocyclophane biosynthesis.
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View Article Onlinethat contain homologs of CylC, CylK, and CylI may allow the
identication of a nostocyclyne-producing strain.
3.2.3. From fatty acid condensation. The biosynthesis of
bacterial dialkylresorcinols (DARs) was rst studied in the 70s
and 80s, with Sankawa and colleagues proving the involvement
of two polyketide chains in the generation of the DAR scaﬀold.66
In 2003, Nowak-Thompson et al.67 provided the rst experi-
mental evidence suggesting that DARs are synthetized by
a head-to-head condensation of two fatty-acid-derived
substrates through the activity of a ketosynthase, DarB, fol-
lowed by a putative aromatase DarA. The two enzymes and an
ACP were found to be encoded by adjacent genes in the genome
of Pseudomonas aurantiaca strain BL915 and gave rise to heter-
ologous production of the DAR 2-hexyl-5-propylresorcinol in
Escherichia coli67 (Fig. 7). More recently, Fuchs et al.7 experi-
mentally showed, through in vivo and in vitro assays, that b-keto-
and a,b-unsaturated-fatty acyl thioesters acted as DarB
substrates and gave rise to carboxy-dialkylcyclohexanediones
(carboxy-CHDs) and CHDs that could potentially act as
substrates for the putative aromatase DarA.7 The authors found
that DarB was a new phylogenetically distinct class of ketosyn-
thase enzyme, which had lost the elongation ability in favor of
the head-to-head fatty acid condensation ability and that darAB
genes are widely spread among bacteria, including in cyano-
bacterial strains belonging to the genera Fischerella and
Microcystis.7Nat. Prod. Rep.The rst characterized cyanobacterial DarAB-like pathway
was the bartoloside BGC (brt) from the cyanobacterium Syn-
echocystis salina LEGE 06155.51 This gene cluster (Fig. 7) is
involved in the biosynthesis of diglycosylated 59–61 and
encodes, apart from DarA and DarB, three glycosyltransferases,
a glycolipid export operon, a CylC homolog and a CylK
homolog, as well as a hypothetical protein. An additional brt
BGC was later reported by Afonso et al.52 from the closely-related
cyanobacterium S. salina LEGE 06099 and is involved in the
biosynthesis of the monoglycosylated 58 and 62–68. Just as in
the previously characterized DarAB system,7 the biosynthesis of
bartolosides is initiated by BrtD (DarB homolog) that connects
the two fatty acid derivative thioesters via Claisen condensation
and simultaneous Michael addition, yielding a carboxy-CHD
(Fig. 7).51 All diglycosylated bartolosides (B–D) are synthetized
by condensation of C16 and C18 fatty acyl-derivatives, namely 2-
octadecenoyl-ACP and 3-oxo-hexadecanoyl-ACP thioesters.
Regarding monoglycosylated bartolosides, the initial substrates
likely have diﬀerent chain lengths (C14–C18), including odd-
chain C15 and C17 a,b-unsaturated fatty acyl-ACP thioesters.
The origin of these odd-chain precursors is still unclear.52
Although brt lacks a dedicated ACP, unlike previous character-
ized DAR clusters, it is foreseen that the ACP-bound fatty acyl
derivatives are recruited from primary metabolism, especially
considering the unlikely participation of acyl-CoA substrates
due to the apparent absence of a canonical b-oxidation pathwayThis journal is © The Royal Society of Chemistry 2019
Fig. 7 Biosynthesis of the bartolosides. Top – prototypical DAR-generating dar gene cluster from Pseudomonas aurantiaca and the two brt
BGCs found in Synechocystis salina strains. Bottom – the brt pathway encodes the production of mono- and di-glycosylated bartolosides.
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View Article Onlinein cyanobacteria.68 By using heterologously-expressed BrtC
(DarA homolog) and BrtD in a coupled assay, Lea˜o et al.51
provided the rst biochemical evidence of DarA enzymes acting
as aromatases, as conversion of the fatty acyl derivative surro-
gates to the DAR backbone of 59–61 was observed only in the
presence of BrtC. Backed by crystallographic data, Mori et al.69
showed that in bacterial stilbene biosynthesis by a DarAB
system (StlC/StlD from Photorhabdus luminescens), decarboxyl-
ation occurs during aromatization, clarifying that carboxy-
CHDs are the substrates for DarA aromatases. Following DAR
backbone generation, the biosynthesis of the bartolosides
should proceed with the decoration of the resorcinol with sugar
moieties, namely xylose and rhamnose by glycosyltransferases
BrtA, E and F (diglycosylated bartolosides) or Brt A and E
(monoglycosylated bartolosides), although it is unclear whether
all these enzymes are involved in the glycosylations. Halogena-
tion (including gem-dichlorination) in the alkyl chains is pre-
dicted to be carried out by the CylC homolog BrtJ. The timing of
halogenation in bartoloside biosynthesis in unclear, but it is
foreseeable that BrtJ—like CylC—acts on ACP tethered fatty acyl
derivatives, i.e., before DAR formation. As for hierridin C (6),
bartoloside D (61) is halogenated in the resorcinol ring but no
additional halogenase has been found in the genome of S. salina
LEGE 06155 that could explain this functionality.51 Intriguingly,This journal is © The Royal Society of Chemistry 2019BrtB enzymes, found in both brt clusters, are CylK homologs that
could alkylate nucleophilic substrates using the mid-chain
halogenated positions in the bartolosides as electrophiles.
Still, such reactivity is not required to explain the biosynthesis of
currently known bartolosides and bartolosides do not have a free
C2 position as do known BrtK nucleophiles.8 Apart from the
biosynthetic genes, the brt cluster also encodes a DevBCA-like
glycolipid export system,70 BrtGHI, which could be responsible
for the presence of bartolosides in spent culture medium or for
potential incorporation into the outer membrane.51
Fuchs et al. reported7 that inMicrocystis sp. PCC 9808, a pair
of DarA and DarB homologs were part of a small BGC that also
encoded two desaturases, a DevBCA exporter system and an
oxygenase (Fig. 8). Taking into consideration such predicted
reactivity, the cluster was proposed to encode microcarbonin A
(69), produced by a Microcystis sp. strain, although there is no
direct experimental evidence supporting this proposal. Hypo-
thetically, the carboxy-CHD resulting from the DarB-mediated
condensation of C14 and C12 fatty acyl derivatives is aroma-
tized by the DarA homolog (Fig. 8). Like bartolosides, micro-
carbonin A BGC also lacks an ACP, suggesting that the fatty-acyl
precursors are obtained from primary metabolism. Potentially
aer DAR formation, the two desaturases likely catalyze the
dehydrogenation of the fatty-acid chains, creating the twoNat. Prod. Rep.
Fig. 8 The DARmicrocarbonin (69) is hypothesized7 to be produced by a BGC found inMicrocystis aeruginosa PCC 9808 (top). The biosynthetic
events eventually leading to 69 are shown (bottom).
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View Article Onlineinternal alkyne moieties. A similar alkyne system is found in 70
and these are of considerable biosynthetic interest. The DevBCA
transporter, as in the case of bartolosides, suggests export to the
outer membrane or to the extracellular medium. The oxygenase
has no corresponding homolog in characterized DAR clusters
and it is unclear what its role might be in the biosynthesis of 69.3.3. Diversity of alkylresorcinol pathways in cyanobacterial
genomes
Genomic data for the phylum Cyanobacteria have been
increasing over the past years, mostly as a result of a few major
sequencing eﬀorts,71–73 but most genera have either none or
a single assembly available publicly. As of August 2018, over
a thousand cyanobacterial genomes were publicly available in
the GenBank database, more than half of which corresponding
to the smaller-genome genera Prochlorococcus and Synecho-
coccus picocyanobacteria. This wealth of genomic data can be
used to obtain a predictive overview of MAR and DAR diversity
(according to currently understood biosynthesis) in the phylum
Cyanobacteria. In fact, Nakamura et al.8 have done this exercise
for CylC/CylK containing cyanobacterial genomes and found
a series of diﬀerent orphan BGC archetypes that likely corre-
spond to unprecedented natural product classes. Likewise,
Costa et al.19 who looked into the distribution of hid-like BGCs
in cyanobacteria observed that these are widely distributed in
picocyanobacteria. Within the scope of this review, we carried
out a distribution analysis of MAR- and DAR-encoding pathways
among currently available cyanobacterial amino acid sequence
data (mostly from genome-sequencing studies) available in the
GenBank. We performed phylogenetic analysis of type III PKSs
(Fig. 9) and DarB homologues (Fig. 10) which overall suggest
that most scaﬀolds of MAR and DAR types are still to be
uncovered in this phylum.‡
Type III PKSs in cyanobacteria are distributed among eight
well-supported clades (Fig. 9). The majority of these enzymes‡ MEGA X soware (URL: www.megasoware.net/) was used to create amino acid
sequence alignments (MUSCLE), phylogenetic model evaluation and ML
phylogenetic tree construction.
Nat. Prod. Rep.are HidC homologs and are found among picocyanobacteria
(hidABC clade) and other Synechococcales (hidCA/hidCBA clade).
These are part of short clusters that include always a methyl-
transferase homolog of HidA and are likely to correspond
exclusively to MAR end-products. The paracyclophane-
associated type III PKSs clade together, as expected, and are,
in turn, closely-related to three additional clades (clades “1”, “2”
and “3”, Fig. 9). One such clade is composed of Microcystis and
Nostoc enzymes, and they are part of clusters that include fatty
acid activation enzymes and type I PKSs. ThreeMoorea spp. type
III PKSs compose “clade 2” and are part of BGCs encoding type I
PKSs and methyltransferases. “Clade 3” is composed of type III
PKS homologs from Cylindrospermum, Cyanothece and Pleuro-
capsa strains. These are encoded within heterogeneous BGCs
that share fatty acid activation and type I PKSs. Interestingly,
from all the BGCs extracted for the three clades closest to the
paracyclophanes clade, only in Cylindrospermum sp. NIES-4074
(“clade 3”) a pair of CylC/CylK homologs was detected, sug-
gesting that all other pathways encode MARs. An additional
cyanobacterial type III PKS clade observed in the phylogenetic
tree (Fig. 9) is composed only of a Moorea and a Roseolum
strain. These homologs are closely related to the actinobacterial
DpgA, that is involved in the biosynthesis of the non-
proteinogenic amino acid 3,5-hydroxyphenylglycine,61 and are
found in small (5 kb) clusters that also encode DpgB (dehy-
dratase that is associated with DpgA). The remaining well-
supported clade of cyanobacterial type III PKSs includes
homologs of MtbPKS18, that takes part in alkylpyrone
biosynthesis in Mycobacterium tuberculosis.74 The potential
alkylpyrone-generating cyanobacterial homologs are part of
relatively small gene clusters (<15 kb), most of which contain
a putative cytochrome b5 (desaturase) adjacent to the type III
PKS.
The DarB phylogeny shows a less diverse topology for cya-
nobacteria, with three related clades with strong bootstrap
support that are closely-related and likely involved in DAR
biosynthesis since they have adjacent DarA homologs (Fig. 10).
One of these clades includes only the two BrtD homologs from
S. salina. Another small clade is composed of two DarB homo-
logs from Microcystis aeruginosa that correspond to potentialThis journal is © The Royal Society of Chemistry 2019
Fig. 9 Phylogenetic diversity of type III PKS enzymes in cyanobacteria. (A) Maximum-likelihood tree (JTT + Gmodel) computed‡ from an amino
acid alignment containing sequences of type III PKS homologs from cyanobacteria (retrieved from the GenBank) as well as characterized
bacterial type III PKSs (shown in bold). (B) – Selected BGCs from each clade (as represented in the phylogenetic tree) of cyanobacterial type III
PKSs, the position of the type III PKS-encoding gene within each BGC is underlined.
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View Article Onlinemicrocarbonin-generating BGCs7 (see also Fig. 8). Considerably
more diversity of BGC archetypes is found within the third
cluster, which comprises homologs from heterocystous Nosto-
cales and Stigonematales strains. The associated BGCs are
relatively large (>25 kb) and encode diverse functionalities
including type I PKSs, DevBCA transporters, acetyltransferases
and oxidoreductases. Most also include CylC/CylK pairs.8
Interestingly, other cyanobacterial DarB homologs have no
DarA homolog in an adjacent position (nor in their immediate
genomic context). These DarB homologs are nevertheless
evolutionarily more distant from their DarA-associatedThis journal is © The Royal Society of Chemistry 2019cyanobacterial counterparts than are those from other bacteria
(including the biochemically characterized DarB and StlD),
which suggests that their reactivity might be diﬀerent from
DarB and, consequently, that their reaction products may not be
carboxy-CHDs. These “DarA-less” DarB enzymes are grouped in
two clades (one with homologs from two Acaryochloris sp.
strains and a larger that encompasses homologs from a wider
variety of genera), as well as a loner Nostoc punctiforme homolog.
The latter (Nostoc) homolog is encoded in a large BGC (60 kb)
that encodes multiple type I PKSs and diﬀerent fatty acid acti-
vating- or modifying functionalities. The BGCs associated withNat. Prod. Rep.
Fig. 10 Phylogenetic diversity of BrtD enzymes in cyanobacteria. (A) Maximum-likelihood tree (JTT + G model) computed‡ from an amino acid
alignment containing sequences of the top BrtD (DarB) homologs from bacteria (retrieved from the GenBank), characterized DarB homologs
(corresponding natural products shown next to taxa), and sequences of other ketosynthases from bacteria (selected based on Fuchs et al.).7 (B)
Selected BGCs from each clade depicted in the phylogenetic tree, darA and darB homologs are underlined * the putative microcarbonin A BGC
assignment is not supported by direct biochemical evidence.
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View Article Onlinethe two clades are more simple and do not contain type I PKSs
(Fig. 10).
Overall, the phylogenetic analysis and annotation of the
genomic context of cyanobacterial type III PKS and DarB
homologs shows that MARs and DARs are produced by a wide
range of cyanobacteria, from the simpler picocyanobacteria to
the cell-diﬀerentiating Nostocales and Stigonematales. For the
overwhelming majority of BGCs that encode these MAR and
DAR-generating enzymes, we cannot currently assign a natural
product. Moreover, these orphan BGCs are diverse in size and
encoded functionalities. Still, and as expected, several fatty acid
activating and modifying enzymes are present in the BGCs.
Interestingly, the presence of CylC/CylK homolog pairs seems
punctuated among the phylogenetic clades and among BGCs ofNat. Prod. Rep.similar architecture. Taking into account that these enzyme
pairs are involved in dimerization or eventually polymerization,
their incorporation in BGCs might result in gain of new func-
tions for the encoded MARs or DARs. Also of considerable
interest is the relatively widespread occurrence of DarB homo-
logs in BGCs without an associated aromatase, whose end-
products remain to be discovered.4. Synthetic approaches to
cyanobacterial alkylresorcinols
The time-consuming growth culture experiments and low yields
obtained for a number of bioactive alkylresorcinols have raised
the need for alternative and more eﬀective means to access andThis journal is © The Royal Society of Chemistry 2019
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View Article Onlinestudy these secondary metabolites. Due to their simple and
planar structure, relatively short and simple organic syntheses
of the monoalkyl derivatives hierridins have been achieved
already in the 1990s. The uniqueness of the [7.7]paracyclophane
scaﬀold has further drawn the attention of the synthetic
community. This has culminated in the development of admi-
rable series of reactions towards the preparation of the dimeric
macrocycles cylindrocyclophanes A (16) and F (25).4.1. Monoalkylresorcinols (MARs)
Many studies have described the synthesis of natural MARs,
employing several approaches to accomplish the critical step of
carbon–carbon bond formation between the resorcinol ring and
the alkyl side chain. In some cases, additions using a Gilman
reagent,75 a Suzuki76 or a Sonogashira3 coupling were adopted;
however, Wittig and Grignard reactions are the most typically
used.77,78 The few procedures dedicated to the synthesis of
hierridins relied on one of the two latter alkylation strategies,
using a readily available brominated or methoxylated salicy-
laldehyde derivative as starting material.Scheme 1 Synthesis of hierridins 4–6 and 8.19,79,80
This journal is © The Royal Society of Chemistry 2019In 1998, Jinno and Okita79 reported the total synthesis of the
yeast-derived alkylphenol phaﬃaol (also known as hierridin A,18
4, see Section 2.1.1.). To this end, 3,5-dibromosalicylaldehyde
(71) was subjected to a Wittig olenation to produce the key
intermediate 72 as a 1 : 1 mixture of E/Z isomers (57% yield).
Reduction of the alkenyl phenol 72 was then carried out by
hydrogenation, providing the alkyl phenol 73. Finally, the
nucleophilic aromatic substitution of the dibromide 73 with
sodium methoxide aﬀorded the expected MAR 4 (67% yield
from 73) (Scheme 1).
The extended chain analogue hierridin (8), isolated from the
lichen Ramalina hierrensis, was synthesized in ve steps by
Gonza´lez and co-workers.80 The phenolic aldehyde precursor o-
vanillin (74) was rst alkylated in the presence of an n-eicosanyl
Grignard reagent to generate compound 75 (yield 65%).
Subsequent hydrogenation followed by oxidation in the pres-
ence of salcomine under a stream of oxygen provided the
quinone intermediate 76, which was further subjected to
sodium dithionite reduction to aﬀord the corresponding
hydroquinone. The methylation of the sterically most accessibleNat. Prod. Rep.
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View Article Onlinehydroxy group by methyliodide and K2CO3 under reux for 24 h
provided hierridin (8) (Scheme 1).
Costa and co-workers19 recently achieved the total synthesis
of hierridin B (5), which contains a 15-carbon length alkyl side
chain moiety. In contrast to the synthetic routes described
above for hierridins 4 and 8, their method used 2-hydroxy-3,5-
dimethoxybenzaldehyde (77) as the initial building block,
avoiding a subsequent methoxylation step in position 5. The
synthesis was thus achieved in only two steps, via Grignard
reaction of 77 to produce the intermediate 78, which was then
hydrogenated to aﬀord 5 in moderate yield (38% from 78)
(Scheme 1). The authors suggested that the methoxy group in
position 5 negatively inuences the eﬃciency of the reduction
step, since the product yield obtained was signicantly lower
than that reported in the synthesis of compound 8 (38% versus >
90%).80
The chlorinated derivative hierridin C (6) has been synthe-
sized concurrently to hierridin B (5).19 Since direct chlorination
of 5 in the appropriate position failed, a procedure consisting in
monohalogenation of 77 prior to the Grignard reaction was
undertaken, but the outcome of the subsequent hydrogenationScheme 2 Ring closing approaches implemented in the syntheses of [7.
heat; (a2) Zn–Hg, HCl, AcOH, heat; (b) AlCl3; (c)25 C to 20 C, then HC
(NH4)6Mo7O24; (f3) KOH/Al2O3, CF2Br2, 0 C to 23 C.
Nat. Prod. Rep.step was unsuccessful. An alternate synthetic route for the
carbon–carbon bond formation was applied, using a similar
approach employed for compound 4. This included the regio-
selective chlorination of 77 to aﬀord the compound 79. Wittig
olenation of 79 followed by palladium-catalyzed hydrogena-
tion led to monoalkylresorcinol 6 (Scheme 1).
These strategies provided 14% to 79% overall recovery of
hierridins. Despite the eﬃciency of the Grignard addition, the
subsequent reactions leading to hierridins 5 or 8 led to
substantial decrease of the global yield. Furthermore, using the
precursor 2-hydroxy-3,5-dimethoxybenzaldehyde (77) as start-
ing material enabled shorter synthesis of 5 and 6. Thus it may
be worthwhile to revisit the synthesis of hierridins 4, 5 and 8 by
involving a Wittig reaction directly on compound 77 to improve
the overall yields.4.2. Dialkylresorcinols (DARs)
Eﬀective synthetic routes to simple natural DARs have
been designed.81,82 In these studies, alkylated a,b-unsatu-
rated ketones and diethylmalonate were subjected to7]paracyclophanes. Reagents and conditions:86–89,91,92 (a1) Na, Me3SiCl,
l; (d) schrock cat.; (e) NaH, cat. 15-crown-5; (f1) NaOMe; (f2) H2O2, cat.
This journal is © The Royal Society of Chemistry 2019
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View Article OnlineMichael addition/Dieckmann condensation followed by
saponication/decarboxylation to generate alkylcyclohexane-
1,3-diones. Diﬀerent strategies were then employed to form
2,5-dialkylresorcinols, involving rst a 2-alkylation, if neces-
sary, prior to aromatization. However, to the best of our
knowledge, the total synthesis of the functionalized cyano-
bacterial DARs bartolosides and microcarbonin A (69) has not
been reported yet.
Cyclophanes possess a more complex architecture, with
a macrocyclic system representing a rigid cavity of great interest
in host–guest chemistry.83 For this reason, their synthesis has
been extensively investigated since the 1950s.40,84,85 From
a synthetic perspective, closure of the ring core accounts for the
most challenging step, which has led to the consideration of
multiple strategies for the formation of such key carbon–carbon
bonds in cyclophanes.83,84 A few of these strategies have been
applied to the total synthesis of compounds from the [7.7]par-
acyclophane series (Scheme 2). Mascal and co-workers86 pro-
ceeded to the synthesis of a diester precursor prior to cyclization
in [7.7]paracyclophane via intramolecular acyloin condensa-
tion. In an attempt to prepare benzocyclononanone, Schubert
et al.87 used high dilution Friedel–Cras reaction between
monoalkylated monomers, which resulted in the fortuitousScheme 3 Synthesis of cylindrocyclophane F (25) by Smith and co-wor
This journal is © The Royal Society of Chemistry 2019synthesis of a [7.7]paracyclophanedione (5% yield). Another
study by Staab and co-workers88 used bis(dithiane) alkylation for
preparation of a tetramethoxy[7.7]paracyclophane-4,17-dione.
As for the synthesis of the C2-symmetric cylindrocyclophanes
A (16) and F (25), head-to-tail cyclodimerizations were per-
formed via more advanced procedures, furnishing diene mac-
rocycles as intermediates. Smith and co-workers89 as well as
Yamakoshi et al.90 employed a tandem cross metathesis/ring-
closing metathesis (RCM). Macrocyclic dimerization by
a double Horner–Wadsworth–Emmons olenation was re-
ported by Hoye et al.91 while Nicolaou and co-workers92 envi-
sioned the Ramberg-Ba¨cklund olenation reaction to
successfully obtain the [7.7]paracyclophane scaﬀold leading to
the formation of 16 and 25.
The natural compounds ()-cylindrocyclophane A (16) and
()-cylindrocyclophane F (25) possess six and four stereo-
centers, respectively. Two strategies were used to obtain the
desired congurations of ()-16 and ()-25. While two groups,
Smith et al.89,93 and Yamakoshi and co-workers,90 introduced all
stereocenters before the dimerization step, two other groups,
Hoye et al.91 and Nicolaou and co-workers92 preferred estab-
lishing only the stereogenic center bearing the n-butyl unit prior
to macrocyclization. Asymmetric syntheses were thereinkers.89,93,95
Nat. Prod. Rep.
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View Article Onlinerequired at the end of the process to settle the desired stereo-
chemistry for hydroxy- and methyl-bearing carbons.
Smith and co-workers reported the rst total synthesis of
cylindrocyclophane F (25) in 1999,93 through a stepwise proce-
dure to prepare the dimer structure before closing the macro-
ring (Scheme 3). The imide 81 was used as starter unit to
construct intermediate 82, ensuring stereocontrol in the initial
step introducing the allyl chain. A Danheiser benzannulation
between 82 and cyclobutenone 83 and subsequent methylation
furnished the resorcinol intermediate 84, which was then con-
verted to iodide 85 and tosyl hydrazone 86. The assembly of 85
and 86 using lithium–halogen exchange followed by Myers
reductive coupling led to compound 87 in 73% yield. Conver-
sion of the latter to diene 88 followed by olenmetathesis using
a Grubbs ruthenium catalyst provided the paracyclophane 89,
which aer hydrogenation and removal of the methyl ethers
aﬀorded cylindrocyclophane F (25).
The same authors published a second-generation synthesis
of compound 25,89 revisiting the macrocycle assembling
strategy through the one-pot cross metathesis/RCM (Scheme 3).Scheme 4 Total synthesis of cylindrocyclophane A (16) by Smith and co
Nat. Prod. Rep.To this end, instead of fragment 83, cyclobutenone 90 was
synthesized and united to siloxyalkyne 82 to form the para-
cyclophane monomer 91. For dimerization of 91, substantial
improvements in reactivity were found in the presence of
Schrock molybdenum catalyst in comparison to Grubbs ruthe-
nium catalysts. Hydrogenation of the diene macrocycle 92 and
cleavage of the methyl ethers aﬀorded cyclindrocyclophane F
(25). While the rst-generation synthesis with 20 steps gave
8.3% overall yield of targeted compound 25, only 11 steps were
required with the second method to result in 22% global yield.94
Since the cross olen metathesis provides the thermody-
namically most favored isomer possessing double bonds with
trans geometry and seven-carbon atom tethers,95 this reaction
was also exploited for the synthesis of the natural hydroxylated
analogue 16. A disconnection study revealed a monomer
hydroxylated on the side alkyl chain, which was synthesized by
Smith and co-workers89 as follows. Stannyl cyclobutenone 93
underwent a Danheiser annulation with compound 82 to
provide aryl iodide 94. Addition of the amide 95 via lithium–
halogen exchange and conversion of the ketone intermediate-workers (A and B) and Yamakoshi and co-workers (C and B).89,90
This journal is © The Royal Society of Chemistry 2019
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View Article Onlineobtained to the corresponding alcohol in a stereoselective
manner provided compound 96 (Scheme 4A). Finally, dimer-
ization of monomer 96 using Schrock catalyst gave the bis(ole-
n) 97, which aﬀorded cylindrocyclophane A (16) aer alcohol
deprotection, hydrogenation and ether demethylation (Scheme
4B). An overall yield of 8.1% was recovered from a total of 16
steps.
The tandem dimerization-macrocyclization scheme devel-
oped by Smith and co-workers in 2000 (ref. 89) was also
implemented by Yamakoshi and co-workers in 2009,90 who
synthesized both cylindrocyclophane A (16) and its non-naturalScheme 5 Synthesis of cylindrocyclophane A (16) by Hoye and co-work
and F (25).91,92
This journal is © The Royal Society of Chemistry 2019dextrorotatory enantiomer (Scheme 4C). A Sonogashira
coupling of syringaldehyde (98) and alkyne 99 prepared from L-
diethyl tartrate resulted in the tetrasubstituted resorcinol 100.
In the synthetic route leading to 16, a diastereocontrolled
reduction of the alkyne led to an intermediary E-alkene, which
was subjected to a Johnson–Claisen rearrangement prior to
a Wittig reaction to establish the n-butyl group. This aﬀorded
benzaldehyde 101 in ten steps with 33% yield. Within eight
subsequent steps, compound 101 underwent a diaster-
eoselective aldolisation in the presence of oxazolidinone 102,
followed by extension of the side alkyl chain via Horner–ers and Nicolaou's approach to synthesise cylindrocyclophanes A (16)
Nat. Prod. Rep.
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View Article OnlineWadsworth–Emmons olenation to furnish the paracyclophane
monomer 96. The nal steps were common to the procedure
adopted by Smith and co-workers, apart from the choice of ring-
closing metathesis catalyst, being a Grubbs second-generation
complex (Scheme 4B). Overall, 3.5% yield of compound 16
was obtained in a 20-step synthesis.
Hoye and co-workers91 also used a resorcinol derivative, 4-
bromo-3,5-dimethoxybenzyl alcohol (103), as starting material
for the total synthesis of cylindrocyclophane A (16) (Scheme 5).
The synthetic route targeted the paracyclophane monomer 106,
which possesses a seven-carbon length side chain bearing the
butyl moiety. To this end, alkene 104 was synthesized in four
steps, prior to enzyme-assisted conversion of the allylic alcohol
to (R)-acetate 105. A [3,3]-sigmatropic rearrangement followed
by reduction of the alkene provided the n-butyl group, while the
ester side chain formed was elongated via Horner–Wadsworth–
Emmons reaction. Transformation to a phosphono ester and
oxidation of the benzylic alcohol furnished the bifunctional
monomeric unit 106, which yielded E,E-diene 107 through
Horner–Wadsworth–Emmons macrocyclic dimerization. In
order to introduce the four stereocenters holding the methyl
and the hydroxy groups, the ester groups were converted to
methyls and stereoselective hydroboration followed by H2O2
oxidation led to the requisite enantiomer 108 (53% yield over
four steps). The nal step entailed an eﬃcient demethylation to
release cylindrocyclophane A (16). This alternate synthetic route
revealed an overall yield of 1.6% obtained in 22 steps.
Furthermore, the olenation reaction that used the saturated
monomer 106 was found to be stereoselective, in contrast to its
(E)-4,5-alkene homologue that led to the formation of a mixture
of stereoisomers.
Nicolaou and co-workers employed a similar building
block to construct the monomer 111 from bromide 109
(Scheme 5).92 Reaction with pentanal and nucleophilic addi-
tion of a vinyl lithium followed by allylic transposition-
oxidation of the resulting tertiary alcohol provided enone
110. This product (110) bears an n-butyl residue and the ve-
atom side chain intended to connect the two resorcinol units.
Subsequent enantioselective ketone reduction and catalytic
olen hydrogenation established the stereochemistry of the
bifunctional monomer precursor 111. The macrocyclization
occurred via displacement of the mesylate substituent to
generate a (bis)thioether, which was further oxidized to
bis(sulfone) 112. With the macrocyclization completed,
a Ramberg–Ba¨cklund reaction of 112 with Chan's modica-
tion provided a bis(olen), which aer asymmetric dihy-
droxylation aﬀorded the macrocyclic diol 113, the common
precursor for the synthesis of both cylindrocyclophanes A (16)
and F (25). Cylindrocyclophane F (25) was obtained with good
yield (71%) via a one-pot sequential reaction including
methylation of the side chains and demethylation of the
methoxy groups. Concomitantly, the route to cylin-
drocyclophane A (16) was envisaged through oxidation of
alcohol to ketone, enol triate formation and cross coupling
with a Grignard reagent to furnish bis(olen) 114. Compound
114 was then subjected to hydroboration, H2O2 oxidation and
ether demethylation according to Hoye's procedure.Nat. Prod. Rep.Nicolaou's approach gave 1.7% (19 steps) and 0.6% (21 steps)
overall yields of paracyclophanes 25 and 16, respectively.
In summary, the syntheses of MARs 4–6 and 8 were based
on alkylation of a salicylaldehyde precursor via Wittig or
Grignard reaction. The synthetic approaches leading to cylin-
drocyclophanes 16 and 25 rst consisted in the preparation of
a tetrasubstituted resorcinol monomer through Danheiser
annulation, Sonogashira coupling followed by Johnson–
Claisen rearrangement, or asymmetric functionalization.
Head-to-tail cyclodimerization then occurred via olen
metathesis, double Horner–Emmons olenation or Ramberg–
Ba¨cklund reaction. Final minor synthetic steps enabled to
release or install functional groups. Thus, conventional
organic synthesis methods have been employed to prepare the
aforementioned compounds (16, 25). In contrast to the
assumed biosynthetic pathways, the resorcinol ring was either
constructed by reaction of a cyclobutenone and an acetylene,
or it was introduced through a commercially available func-
tionalized aromatic derivative. Moreover, the macrocycle
assembling step required p-substituted monomers, in contrast
to the suggested natural dimerization of the resorcinol ring
and the non-functionalized alkyl chain. As an alternative to
conventional syntheses of natural products, biomimetic
approaches have become popular in the last twenty years,
revealing new powerful synthetic routes and enabling to
conrm or invalidate biosynthetic hypotheses.96 Such
a strategy has, for instance, been applied to the naturally
occurring paracyclophane dimer longithorone A.97 Despite the
challenging linkage formation at C(7) and C(20) and the
conguration of the stereocenters, similar approaches
mimicking natural biosynthetic pathways may open up new
prospects towards eﬃcient organic synthesis and stereo-
chemical elucidation of cyanobacterial DAR series.
5. Conclusions
Only a small fraction of cyanobacterial alkylresorcinol diversity
has been documented, but it is now evident that these structural
motifs are present throughout the phylum. In particular, the
DAR motif seems to be so relevant for cyanobacterial ecophys-
iology that two fundamentally diﬀerent biosynthetic pathways
have converged to create it in the same bacterial phylum. This is
remarkable since there are limited known examples of
mechanistically-distinct natural product biosynthetic pathways
that have converged to create the same scaﬀold, and even then
this usually occurs in separate kingdoms.69,98,99 Despite the
dissimilar biochemistry involved in creating the DAR moiety
through MAR biosynthesis followed by Friedel–Cras alkylation
or by head-to-head condensation of fatty acyl precursors,
a number of decorations to the DAR scaﬀold are installed for
both pathways, including internal alkynes, glycosylation and
halogenation. Illustrative of this are the pairs of CylC and CylK
homologs that are found in a considerable diverse set of cya-
nobacterial gene clusters of DarAB but also type III PKS
biosynthetic origin. These shared features likely reect evolu-
tionary pressure associated with the DAR skeleton in cyano-
bacteria and are probably reminiscent of related ecologicalThis journal is © The Royal Society of Chemistry 2019
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View Article Onlineroles. Still, and contrary to what is known for MARs and DARs
produced by other bacteria15,100 current understanding of the
functions that cyanobacterial alkylresorcinols may play in the
natural setting is minimal, although many have potent biolog-
ical activity in pharmacologically-relevant assays. The uncov-
ered diversity of alkylresorcinols in cyanobacteria represents an
opportunity to perform genome-guided isolation eﬀorts that
have the potential to reveal new compound classes and
important bioactivities; the study of their ecological roles will
nevertheless remain a challenge.6. Conﬂicts of interest
There are no conicts to declare.7. Acknowledgements
This work was funded by the BLUEandGREEN project (H2020
TWINNING, Grant Agreement no. 692419) and was further
supported by an European Research Council (ERC) Starting
Grant (759840) to PNL and National Science Foundation (NSF)
through grant CHE-1454007 to EPB. We acknowledge funding
by Fundaça˜o para a Cieˆncia e a Tecnologia (FCT) through
projects PTDC/BIA-BQM/29710/2017 (co-nanced by COMPETE
2020, Portugal 2020, ERDF) UID/Multi/04423/2013, as well as
through scholarship SFRH/BD116009/2016 to SF and grant IF/
01358/2014 to PNL.8. Notes and references
1 A. Kozubek and J. H. P. Tyman, Chem. Rev., 1999, 99, 1–26.
2 M. Stasiuk and A. Kozubek, Cell. Mol. Life Sci., 2010, 67,
841–860.
3 H. Kikuchi, I. Ito, K. Takahashi, H. Ishigaki, K. Iizumi,
Y. Kubohara and Y. Oshima, J. Nat. Prod., 2017, 80, 2716–
2722.
4 M. B. Austin and J. P. Noel, Nat. Prod. Rep., 2003, 20, 79–110.
5 S. R. Baerson, J. Schro¨der, D. Cook, A. M. Rimando, Z. Pan,
F. E. Dayan, B. P. Noonan and S. O. Duke, Plant Signaling
Behav., 2010, 5, 1286–1289.
6 H. Nakamura, H. A. Hamer, G. Sirasani and E. P. Balskus, J.
Am. Chem. Soc., 2012, 134, 18518–18521.
7 S. W. Fuchs, K. A. J. Bozhu¨yu¨k, D. Kresovic, F. Grundmann,
V. Dill, A. O. Brachmann, N. R. Watereld and H. B. Bode,
Angew. Chem., Int. Ed., 2013, 52, 4108–4112.
8 H. Nakamura, E. E. Schultz and E. P. Balskus, Nat. Chem.
Biol., 2017, 13, 916–921.
9 J.-Z. Deng, S. R. Starck and S. M. Hecht, J. Nat. Prod., 1999,
62, 477–480.
10 Y.-M. Gao, T.-Y. Sun, M. Ma, G.-D. Chen, Z.-Q. Zhou,
C.-X. Wang, D. Hu, L.-G. Chen, X.-S. Yao and H. Gao,
Fitoterapia, 2016, 112, 254–259.
11 N. Tsuge, M. Mizokami, S. Imai, A. Shimazu and H. Seto, J.
Antibiot., 1992, 45, 886–891.
12 A. Kozubek, S. Pietr and A. Czerwonka, J. Bacteriol., 1996,
178, 4027–4030.This journal is © The Royal Society of Chemistry 201913 T. Hayashi, Y. Kitamura, N. Funa, Y. Ohnishi and
S. Horinouchi, ChemBioChem, 2011, 12, 2166–2176.
14 R. N. Reusch and H. L. Sadoﬀ, J. Bacteriol., 1979, 139, 6.
15 R. N. Reusch and H. L. Sadoﬀ, Nature, 1983, 302, 268–270.
16 N. Funa, H. Ozawa, A. Hirata and S. Horinouchi, Proc. Natl.
Acad. Sci. U. S. A., 2006, 103, 6356–6361.
17 M. Funabashi, N. Funa and S. Horinouchi, J. Biol. Chem.,
2008, 283, 13983–13991.
18 O. Papendorf, G. M. Ko¨nig and A. D. Wright, Phytochemistry,
1998, 49, 2383–2386.
19 M. Costa, I. E. Sampaio-Dias, R. Castelo-Branco,
H. Scharfenstein, R. Rezende de Castro, A. Silva,
M. P. C. Schneider, M. J. Arau´jo, R. Martins,
V. F. Domingues, F. Nogueira, V. M. Vasconcelos and
P. N. Lea˜o, ChemRxiv, 2018, DOI: 10.26434/
chemrxiv.7090526.v1.
20 M. Preisitsch, T. H. J. Niedermeyer, S. E. Heiden,
I. Neidhardt, J. Kumpfmu¨ller, M. Wurster, K. Harmrolfs,
C. Wiesner, H. Enke, R. Mu¨ller and S. Mundt, J. Nat.
Prod., 2016, 79, 106–115.
21 J. D. Bu'Lock and A. T. Hudson, J. Chem. Soc. C, 1969, 61–63.
22 M. Kumagai, Y. Suhara, T. Aoyagi and H. Umezawa, J.
Antibiot., 1971, 24, 870–875.
23 A. G. Gonza´lez, J. B. Barrera, E. M. R. Perez and
C. E. H. Padron, Planta Med., 1992, 58, 214–218.
24 W. Horper and F. J. Marner, Nat. Prod. Lett., 1995, 6, 163–
170.
25 S. Jinno, K. Hata, N. Shimidzu and T. Okita, J. Antibiot.,
1998, 51, 508–511.
26 P. N. Lea˜o, M. Costa, V. Ramos, A. R. Pereira,
V. C. Fernandes, V. F. Domingues, W. H. Gerwick,
V. M. Vasconcelos and R. Martins, PLoS One, 2013, 8,
e69562.
27 S. Freitas, R. Martins, M. Costa, P. N. Lea˜o, R. Vitorino,
V. Vasconcelos and R. Urbatzka, Mar. Drugs, 2016, 14,
158.
28 H. Kikuchi, I. Ito, K. Takahashi, H. Ishigaki, K. Iizumi,
Y. Kubohara and Y. Oshima, J. Nat. Prod., 2017, 80, 2716–
2722.
29 M. Berks, D. Traynor, I. Carrin, R. H. Insall and R. R. Kay,
Dev. Suppl., 1991, 1, 131–139.
30 A. Dubois, C. Ginet, N. Furstoss, A. Belaid, M. A. Hamouda,
W. El Manaa, T. Cluzeau, S. Marchetti, J. E. Ricci, A. Jacquel,
F. Luciano, M. Driowya, R. Benhida, P. Auberger and
G. Robert, OncoTargets Ther., 2016, 7, 26120–26136.
31 H. Reichenbach, H. Kleinig and H. Achenbach, Arch.
Microbiol., 1974, 101, 131–144.
32 T. Kitahara and N. Kanda, J. Antibiot., 1975, 28, 943–946.
33 H. Reichenbach, W. Kohl, A. Bo¨ttger-Vetter and
H. Achenbach, Arch. Microbiol., 1980, 126, 291–293.
34 S. Kato, K. Shindo, H. Kawai, M. Matsuoka and
J. Mochizuki, J. Antibiot., 1993, 46, 1024–1026.
35 A. Pohanka, J. Levenfors and A. Broberg, J. Nat. Prod., 2006,
69, 654–657.
36 T. A. Scho¨ner, S. W. Fuchs, B. Reinhold-Hurek and
H. B. Bode, PLoS One, 2014, 9, e90922.Nat. Prod. Rep.
Natural Product Reports Review
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 3
1 
Ja
nu
ar
y 
20
19
. D
ow
nl
oa
de
d 
on
 2
/1
/2
01
9 
8:
37
:1
7 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online37 T. A. Scho¨ner, D. Kresovic and H. B. Bode, Appl. Microbiol.
Biotechnol., 2015, 99, 8323–8328.
38 B. S. Moore, J. L. Chen, G. M. L. Patterson, R. E. Moore,
L. S. Brinen, Y. Kato and J. Clardy, J. Am. Chem. Soc.,
1990, 112, 4061–4063.
39 B. S. Moore, J.-L. Chen, G. M. L. Patterson and R. E. Moore,
Tetrahedron, 1992, 48, 3001–3006.
40 D. J. Cram and H. Steinberg, J. Am. Chem. Soc., 1951, 73,
5691–5704.
41 Modern Cyclophane Chemistry, ed. R. Gleiter and H. Hopf,
Wiley-Blackwell, 2005, pp. i–xx.
42 G. E. Chlipala, M. Sturdy, A. Krunic, D. D. Lantvit, Q. Shen,
K. Porter, S. M. Swanson and J. Orjala, J. Nat. Prod., 2010,
73, 1529–1537.
43 J. L. Chen, R. E. Moore and G. M. L. Patterson, J. Org. Chem.,
1991, 56, 4360–4364.
44 H. T. N. Bui, R. Jansen, H. T. L. Pham and S. Mundt, J. Nat.
Prod., 2007, 70, 499–503.
45 S. Luo, H.-S. Kang, A. Krunic, G. E. Chlipala, G. Cai,
W.-L. Chen, S. G. Franzblau, S. M. Swanson and J. Orjala,
Tetrahedron Lett., 2014, 55, 686–689.
46 M. Preisitsch, K. Harmrolfs, H. T. Pham, S. E. Heiden,
A. Fu¨ssel, C. Wiesner, A. Pretsch, M. Swiatecka-
Hagenbruch, T. H. Niedermeyer, R. Mu¨ller and S. Mundt,
J. Antibiot., 2015, 68, 165–177.
47 H.-S. Kang, B. D. Santarsiero, H. Kim, A. Krunic, Q. Shen,
S. M. Swanson, H. Chai, A. D. Kinghorn and J. Orjala,
Phytochemistry, 2012, 79, 109–115.
48 D. S. May, W.-L. Chen, D. D. Lantvit, X. Zhang, A. Krunic,
J. E. Burdette, A. Eustaquio and J. Orjala, J. Nat. Prod.,
2017, 80, 1073–1080.
49 D. S. May, H.-S. Kang, B. D. Santarsiero, A. Krunic, Q. Shen,
J. E. Burdette, S. M. Swanson and J. Orjala, J. Nat. Prod.,
2018, 81, 572–578.
50 M. Shaaban, R. P. Maskey, I. Wagner-Do¨bler and
H. Laatsch, J. Nat. Prod., 2002, 65, 1660–1663.
51 P. N. Lea˜o, H. Nakamura, M. Costa, A. R. Pereira,
R. Martins, V. Vasconcelos, W. H. Gerwick and
E. P. Balskus, Angew. Chem., Int. Ed., 2015, 54, 11063–11067.
52 T. B. Afonso, M. S. Costa, R. Rezende de Castro, S. Freitas,
A. Silva, M. P. C. Schneider, R. Martins and P. N. Lea˜o, J.
Nat. Prod., 2016, 79, 2504–2513.
53 D. Beresovsky, O. Hadas, A. Livne, A. Sukenik, A. Kaplan
and S. Carmeli, Isr. J. Chem., 2006, 46, 79–87.
54 A. Ploutno and S. Carmeli, J. Nat. Prod., 2000, 63, 1524–
1526.
55 B. Shen, Hindra, X. Yan, T. Huang, H. Ge, D. Yang, Q. Teng,
J. D. Rudolf and J. R. Lohman, Bioorg. Med. Chem. Lett.,
2015, 25, 9–15.
56 Y. Shimizu, H. Ogata and S. Goto, ChemBioChem, 2017, 18,
50–65.
57 T.-L. Li, O. W. Choroba, H. Hong, D. H. Williams and
J. B. Spencer, Chem. Commun., 2001, 20, 2156–2157.
58 D. Yu, F. Xu, J. Zeng and J. Zhan, IUBMB Life, 2012, 64, 285–
295.
59 A. Parvez, S. Giri, G. R. Giri, M. Kumari, R. Bisht and
P. Saxena, Sci. Rep., 2018, 8, 6529.Nat. Prod. Rep.60 C. Nakano, H. Ozawa, G. Akanuma, N. Funa and
S. Horinouchi, J. Bacteriol., 2009, 191, 4916–4923.
61 V. Pfeifer, G. J. Nicholson, J. Ries, J. Recktenwald,
A. B. Schefer, R. M. Shawky, J. Schro¨der, W. Wohlleben
and S. Pelzer, J. Biol. Chem., 2001, 276, 38370–38377.
62 S. C. Bobzin and R. E. Moore, Tetrahedron, 1993, 49, 7615–
7626.
63 H. Nakamura and E. P. Balskus, Synlett, 2013, 24, 1464–
1470.
64 M. Preisitsch, S. Heiden, M. Beerbaum, T. Niedermeyer,
M. Schneefeld, J. Herrmann, J. Kumpfmu¨ller, A. Thu¨rmer,
I. Neidhardt, C. Wiesner, R. Daniel, R. Mu¨ller,
F.-C. Bange, P. Schmieder, T. Schweder and S. Mundt,
Mar. Drugs, 2016, 14, 21.
65 P. K. Sydor, S. M. Barry, O. M. Odulate, F. Barona-Gomez,
S. W. Haynes, C. Corre, L. Song and G. L. Challis, Nat.
Chem., 2011, 3, 388–392.
66 U. Sankawa, H. Shimada and K. Yamasaki, Chem. Pharm.
Bull., 1981, 29, 3601–3605.
67 B. Nowak-Thompson, P. E. Hammer, D. S. Hill, J. Staﬀord,
N. Torkewitz, T. D. Gaﬀney, S. T. Lam, I. Molna´r and
J. M. Ligon, J. Bacteriol., 2003, 185, 860–869.
68 S. von Berlepsch, H.-H. Kunz, S. Brodesser, P. Fink,
K. Marin, U.-I. Flu¨gge and M. Gierth, Plant Physiol., 2012,
159, 606–617.
69 T. Mori, T. Awakawa, K. Shimomura, Y. Saito, D. Yang,
H. Morita and I. Abe, Cell Chem. Biol., 2016, 23, 1468–1479.
70 G. Fiedler, M. Arnold, S. Hannus and I. Maldener, Mol.
Microbiol., 1998, 27, 1193–1202.
71 P. M. Shih, D. Wu, A. Lati, S. D. Axen, D. P. Fewer, E. Talla,
A. Calteau, F. Cai, N. Tandeau de Marsac, R. Rippka,
M. Herdman, K. Sivonen, T. Coursin, T. Laurent,
L. Goodwin, M. Nolan, K. W. Davenport, C. S. Han,
E. M. Rubin, J. A. Eisen, T. Woyke, M. Gugger and
C. A. Kerfeld, Proc. Natl. Acad. Sci. U. S. A., 2013, 110,
1053–1058.
72 T. Dagan, M. Roettger, K. Stucken, G. Landan, R. Koch,
P. Major, S. B. Gould, V. V. Goremykin, R. Rippka,
N. Tandeau de Marsac, M. Gugger, P. J. Lockhart,
J. F. Allen, I. Brune, I. Maus, A. Pu¨hler and W. F. Martin,
Genome Biol. Evol., 2013, 5, 31–44.
73 S. J. Biller, P. M. Berube, J. W. Berta-Thompson, L. Kelly,
S. E. Roggensack, L. Awad, K. H. Roache-Johnson,
H. Ding, S. J. Giovannoni, G. Rocap, L. R. Moore and
S. W. Chisholm, Sci. Data, 2014, 1, 140034.
74 P. Saxena, G. Yadav, D. Mohanty and R. S. Gokhale, J. Biol.
Chem., 2003, 278, 44780–44790.
75 S. Combes and J.-P. Finet, Synth. Commun., 1997, 27, 3769–
3778.
76 A. Fu¨rstner and G. Seidel, J. Org. Chem., 1997, 62, 2332–
2336.
77 Y. Zhu, D. N. Soroka and S. Sang, J. Agric. Food Chem., 2012,
60, 8624–8631.
78 M. Ortega, J. Pantoja, C. de los Reyes, E. Zub´ıa, M. J. Ortega,
J. J. Pantoja, C. de los Reyes and E. Zub´ıa,Mar. Drugs, 2017,
15, 344.This journal is © The Royal Society of Chemistry 2019
Review Natural Product Reports
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 3
1 
Ja
nu
ar
y 
20
19
. D
ow
nl
oa
de
d 
on
 2
/1
/2
01
9 
8:
37
:1
7 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online79 S. Jinno and T. Okita, Chem. Pharm. Bull., 1998, 46, 1688–
1694.
80 A. G. Gonza´lez, J. Bermejo Barrera and E. M. Rodriguez
Perez, Phytochemistry, 1992, 31, 1436–1439.
81 M. Kronenwerth, C. Dauth, M. Kaiser, I. Pemberton and
H. B. Bode, Eur. J. Org. Chem., 2014, 2014, 8026–8028.
82 R. Madhavachary and D. B. Ramachary, Eur. J. Org. Chem.,
2014, 2014, 7317–7323.
83 T. Gulder and P. S. Baran,Nat. Prod. Rep., 2012, 29, 899–934.
84 S. Kotha, M. E. Shirbhate and G. T. Waghule, Beilstein J. Org.
Chem., 2015, 11, 1274–1331.
85 P. G. Ghasemabadi, T. Yao and G. J. Bodwell, Chem. Soc.
Rev., 2015, 44, 6494–6518.
86 M. Mascal, J.-L. Kerdelhue´, A. S. Batsanov and M. J. Begley,
J. Chem. Soc., Perkin Trans. 1, 1996, (1), 1141–1151.
87 W. M. Schubert, W. A. Sweeney and H. K. Latourette, J. Am.
Chem. Soc., 1954, 76, 5462–5466.
88 H. A. Staab, G. Matzke and C. Krieger, Chem. Ber., 1987, 120,
89–91.
89 A. B. Smith, S. A. Kozmin, C. M. Adams and D. V. Paone, J.
Am. Chem. Soc., 2000, 122, 4984–4985.
90 H. Yamakoshi, F. Ikarashi, M. Minami, M. Shibuya,
T. Sugahara, N. Kanoh, H. Ohori, H. Shibata and
Y. Iwabuchi, Org. Biomol. Chem., 2009, 7, 3772–3781.This journal is © The Royal Society of Chemistry 201991 T. R. Hoye, P. E. Humpal and B. Moon, J. Am. Chem. Soc.,
2000, 122, 4982–4983.
92 K. C. Nicolaou, Y.-P. Sun, H. Korman and D. Sarlah, Angew.
Chem., Int. Ed., 2010, 49, 5875–5878.
93 A. B. Smith, S. A. Kozmin and D. V. Paone, J. Am. Chem. Soc.,
1999, 121, 7423–7424.
94 A. B. Smith, C. M. Adams, S. A. Kozmin and D. V. Paone, J.
Am. Chem. Soc., 2001, 123, 5925–5937.
95 A. B. Smith, C. M. Adams and S. A. Kozmin, J. Am. Chem.
Soc., 2001, 123, 990–991.
96 M. Razzak and J. K. D. Brabander, Nat. Chem. Biol., 2011, 7,
865–875.
97 M. E. Layton, C. A. Morales and M. D. Shair, J. Am. Chem.
Soc., 2002, 124, 773–775.
98 R. S. Nett, M. Montanares, A. Marcassa, X. Lu, R. Nagel,
T. C. Charles, P. Hedden, M. C. Rojas and R. J. Peters,
Nat. Chem. Biol., 2017, 13, 69–74.
99 A. C. Huang, S. A. Kautsar, Y. J. Hong, M. H. Medema,
A. D. Bond, D. J. Tantillo and A. Osbourn, Proc. Natl.
Acad. Sci. U. S. A., 2017, 114, E6005–E6014.
100 S. Brameyer, D. Kresovic, H. B. Bode and R. Heermann,
Proc. Natl. Acad. Sci. U. S. A., 2015, 112, 572–577.Nat. Prod. Rep.
